2022
Accelerated epigenetic aging in newborns with Down syndrome
Xu K, Li S, Muskens IS, Elliott N, Myint SS, Pandey P, Hansen HM, Morimoto LM, Kang AY, Ma X, Metayer C, Mueller BA, Roberts I, Walsh KM, Horvath S, Wiemels JL, de Smith A. Accelerated epigenetic aging in newborns with Down syndrome. Aging Cell 2022, 21: e13652. PMID: 35661546, PMCID: PMC9282838, DOI: 10.1111/acel.13652.Peer-Reviewed Original ResearchConceptsDown syndromeAge accelerationEpigenetic age accelerationGestational age accelerationEarly-onset Alzheimer's diseaseTransient abnormal myelopoiesisPotential confounding factorsEpigenetic agingPremature agingSomatic GATA1 mutationsDS patientsAbnormal myelopoiesisBlood cell proportionsNewbornsAlzheimer's diseaseConfounding factorsBrain tissueCell proportionGATA1 mutationsEndocrine systemBloodTargeted sequencingSomatic mutationsSyndromeDisease
2019
Immunoepidemiology of Cancer
Ma X, Wang R. Immunoepidemiology of Cancer. 2019, 215-224. DOI: 10.1007/978-3-030-25553-4_13.Peer-Reviewed Original ResearchImmune system functionTypes of cancerImmunological factorsCancer immunotherapyTreatment modalitiesChronic diseasesRadiation therapyEpidemiological studiesDrug AdministrationImmunotherapyInfectious diseasesCancerDiseaseExciting new eraSystem functionChemotherapySurgeryImmunoepidemiologyEtiologyTherapyYearsInfectionAdministrationImportant role
2015
Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods
Feinstein AJ, Long J, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Affairs 2015, 34: 592-600. PMID: 25847641, DOI: 10.1377/hlthaff.2014.1119.Peer-Reviewed Original ResearchConceptsStage II diseaseStage III diseaseCancer-related costsCancer careBreast cancerMedian costSurvival rateEnd Results Program-MedicareFive-year survivalCancer care costsBreast surgerySurvival outcomesImproved outcomesOlder womenRadiation therapyCare costsStage IIDiseaseStudy periodWomenCancerCareSignificant national attentionOutcomesPercent
2012
Epidemiology of Myelodysplastic Syndromes
Ma X. Epidemiology of Myelodysplastic Syndromes. The American Journal Of Medicine 2012, 125: s2-s5. PMID: 22735748, PMCID: PMC3394456, DOI: 10.1016/j.amjmed.2012.04.014.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeIncidence of MDSBetter risk-stratify patientsClonal hematopoietic stem cell malignanciesHematopoietic stem cell malignanciesRisk-stratify patientsStem cell malignanciesMore effective treatmentsMDS prognosisDifferent comorbiditiesPrognostic factorsSignificant morbidityEtiologic factorsDisease burdenPoor survivalEffective treatmentCell malignanciesHigh mortalityNew casesHeterogeneous groupComorbiditiesSyndromeDiseaseRecent studiesPotential interactions